Kedrion Highlights Earlier Diagnosis of Acquired Immune Deficits
An expert call highlighted by Kedrion links earlier recognition of acquired immune deficits to the growing use of immunosuppressive and biological therapies.
· 6 min read
Biotech Today — News From The Biotech Space
Liquidia Rebounds as Inquiry Follows Reported 57.2% Drop
Liquidia shares rebound as Kirby McInerney seeks investors for a securities investigation, but the reported selloff's cause and timing remain unclear.
· 6 min read
Biotech Markets
Wed Oct 14 2026 · New York- Nasdaq Biotech 6,876.95 NASDAQ Biotechnology +112.73 +1.67%
- SPDR S&P Biotech $147.08 State Street SPDR S&P Biotech +0.27 +0.19%
- iShares Biotech $203.52 iShares Biotechnology ETF +3.50 +1.75%
- Amgen $427.78 Amgen Inc. +14.94 +3.62%
- Vertex $497.06 Vertex Pharmaceuticals +11.84 +2.44%
- Regeneron $780.78 Regeneron Pharmaceuticals +27.66 +3.67%
- S&P 500 7,702.53 -102.92 -1.32%
- Nasdaq Composite 26,655.33 -549.05 -2.02%
- Dow 30 51,430.50 Dow Jones Industrial Average -239.60 -0.46%
- Russell 2000 2,724.06 -59.31 -2.13%
- US 10Y 5.190% 10-Year Bond -0.027 -0.52%
- VIX 17.07 CBOE Volatility Index +1.80 +11.79%
- Eli Lilly $1,210.51 Eli Lilly and Company +44.00 +3.77%
- Novo Nordisk $38.22 Novo Nordisk A/S +0.16 +0.41%
- Johnson & Johnson $253.39 +4.78 +1.92%
- Merck & Co. $147.15 Merck & Company, Inc. +5.17 +3.64%
- Pfizer $29.34 Pfizer, Inc. +0.97 +3.41%
- AbbVie $284.68 AbbVie Inc. +10.32 +3.76%
- Thermo Fisher $677.14 Thermo Fisher Scientific Inc +14.10 +2.13%
- Danaher $225.17 Danaher Corporation +2.33 +1.05%
- Illumina $268.88 Illumina, Inc. -2.30 -0.85%
- Intuitive Surgical $417.64 Intuitive Surgical, Inc. -4.42 -1.05%
- Boston Scientific $42.51 Boston Scientific Corporation -0.80 -1.85%
- Stryker $280.63 Stryker Corporation -1.92 -0.68%
Delayed market data by Yahoo Finance
Beam’s Early Trial Tests Mutation Repair in Rare Disease
BioNTech Cancer Shot Falls Short on Tumor Progression
Paradigm’s SD-101 Earns Repeat Prix Galien Nomination
Incyte Honors MPN Community Champions in 2026 Awards
Neurocrine Faces Rare-Disease Drug Safety Scrutiny
VERAXA’s BiTAC-ADC Debut Puts Living-System Data in Focus
Insilico Adds Oral Autoimmune Drug to Preclinical Pipeline
Nurix Begins Phase 3 Dosing in DAYBreak CLL-306 Trial
Bristol Myers Squibb’s Admilparant Meets Phase 3 Trial Goal
BridgeBio Advances Encaleret Data and Starts Phase 3 Dosing
Sebela to Detail Tegoprazan Relief Across Reflux Symptoms
BioMarin to Present VOXZOGO Data on Skull-Base Growth
Phanes CEO Ming Wang to Join Boston Healthcare Gathering
Danaher Names Comas and Hershberg to Board of Directors
ARPA-H Funds Push to Ease Cell Therapy Storage Demands
Penicillin’s Hidden Chemistry Offers New Research Clues
Bob Foster Leaves HHS; Legal Succession Remains Unclear
Blood Cancer United Debuts Awards at New York Summit
AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
JNJ Earnings and FDA Deadlines Frame Biotech’s Next Test
Biotech IPO Flow Continues as DayOne Enters US Queue
Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context
Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
Aspen Neuroscience Seeks IPO Funding for Parkinson’s Cells
City Therapeutics and Iambic Aim for Biotech IPO Funding
Beta Bionics Faces Securities Suit Over iLet Compliance
AN2 Therapeutics Faces Shareholder Probe of Board Duties
Celldex Directors Under Review in Shareholder Investigation
Vitalize Raises $31 Million for Hospital Labor Management
Weekly Market Review – Sept. 20, 2025
Equity markets continued their positive momentum this week, with major indices posting solid gains following the Federal Reserve's first rate cut of 2025. The main stock market index of United States, the US500, rose to…
XBI
147.07
+0.19%
IBB
203.52
+1.75%
S&P 500
7,702.71
−1.32%
NASDAQ 100
29,930.66
−2.09%
Change on the prior close · delayed · as of Oct 14, 2:32 PM ET
The Biotech Today briefing
Trials, approvals and the deals moving biotech, in your inbox. Free.
Thanks — you're subscribed.